| abstract |
At least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to achieve at least one result that is one or more of (i) improvement in a physiological state linked to metabolic fatigue in one or more cells, (ii) increased mitochondrial energy and mitochondrial calcium uptake in one or more cells, and/or (iii) treatment or prevention of a calcium deficiency / depletion disorder. Additionally or alternatively, the method can treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof. |